Standard Biotools Valuation

Standard Biotools Investor Information

About 78.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.89. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Standard Biotools has Price/Earnings To Growth (PEG) ratio of 0.31. The company recorded a loss per share of 0.15. The firm had not issued any dividends in recent years. Standard Biotools completed a stock split on 6th of December 2001. Standard Biotools demonstrates evolving financial positioning based on liquidity, leverage, and earnings indicators. Current profitability metrics are under pressure, reflecting a period of reduced earnings capacity. Earnings quality, debt coverage, and cash generation are the primary financial strength indicators for Standard Biotools.

Standard Biotools Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Standard Biotools has an asset utilization ratio of 15.03 percent. This suggests that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Standard Biotools is more efficient with each dollar of assets it utilizes for everyday operations.

Standard Biotools Profitability Analysis

Based on Standard Biotools' profitability indicators, Standard Biotools may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Standard Biotools' ability to earn profits and add value for shareholders.Currently, Gross Profit is projected to increase significantly based on multi-year reporting trends. In the prior fiscal year, Gross Profit was reported at 42.54 Million. As of now, The current year's Gross Profit Margin is projected to rise to 0.62, whereas Pretax Profit Margin is moving lower toward -1.19 .

	Current Value	Last Year	Change From Last Year	10 Year Trend
Gross Profit Margin	0.62	0.4986	Fairly Up	Slightly volatile

Standard Biotools Earnings per Share Projection vs Actual

By analyzing Standard Biotools' earnings estimates, investors can diagnose trend shifts in analyst expectations and compare EPS projections across timeframes. EPS is most informative when read together with margin stability and cash-flow conversion. EPS forecast analysis for Standard Biotools is useful, but investors should remember that consensus numbers often reflect a normalized estimate rather than a full reconstruction of every accounting detail. Standard Biotools is projected to generate -0.01 in earnings per share on 30th of June 2026. Future earnings-per-share expectations are often a key input when investors test valuation assumptions and momentum into the next quarter.

Standard Biotools Ownership Allocation

The majority of Standard Biotools' outstanding shares are owned by institutional holders. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors. Standard Biotools has approximately 78% of its outstanding shares held by institutional investors, 3% by insiders, and 19% in public hands.

Standard Biotools Profitability Analysis

The company reported last year's revenue of 85.33 M. Reported Net Loss for the year was -74.9 M with profit before taxes, overhead, and interest of 42.54 M.

Valuation work on Standard Biotools becomes more reliable when investors compare several lenses at once, including market value, enterprise value. revenue scale, and expected cash-flow durability. The better valuation questions are comparative: what is the market paying for each dollar of revenue, profit, and asset base, and is that premium justified?